Cebranopadol 600 µg

DRUG3 trials

Sponsors

Tris Pharma, Inc.

Conditions

Chronic PainDiabetes MellitusDiabetic NeuropathiesHuman Abuse PotentialPain

Phase 1

Assessment of Abuse Potential of Cebranopadol in Humans

CompletedNCT05256108

Tris Pharma, Inc.Human Abuse Potential

Start: 2022-03-28End: 2022-07-12Updated: 2022-07-27

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

CompletedNCT05491785

Tris Pharma, Inc.Pain

Start: 2022-07-29End: 2024-01-02Updated: 2024-05-09

Phase 2

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

CompletedNCT01939366

Tris Pharma, Inc.Chronic Pain, Diabetes Mellitus, Diabetic Neuropathies

Start: 2013-09-27End: 2015-01-28Updated: 2021-07-15